I believe it a license you pay for annually, anywhere between 2-5k
The trial with beyond blood is a two year trial minimum…. So years down the line….
No I am still heavily invested however I have the right to question the facts of matter which are facts and point that the BOD have failed us in recent years.
Also they talk about 5 contracts pretty much on pen to paper and another x in discussion.
If those 5 contracts aren’t signed and converted then the BOD will look like fools again as they are talking about “potential contacts in the future” effectively all these “potentials” already look priced in….
Realistic this is going to be a long long way back to any for of recovery IN MY OPINION…
I’ll just leave this now, as clearly people don’t like a Factual opinion.
I think the prostate cancer dosing app is what’s killed this…. Basically stating it’s years down the line…..after previously stating Dosemerx was a route to comersalisation
Not sure there was a dozen there was 5 I believe that we’re pretty much over the line but the rest where tentative.
Concern for me is that contracts are being won and it’s not shifting the SP as frankly the BOD are disinterested in MC, Market Value, Shareholders dialog and current performance.
And you can bet your bottoms dollar the next RNS that comes which is a contract will have zero value attached to it ….therefore won’t move the SP again - could be AZN and it still wouldn’t make a difference
Kinda valid point though
Think they need to understand the market and understand there obligation to shareholders.
This RNS (REACH) news has sent the SP down.
There needs to be a material RNS very soon or this will slowly drift.
I think the board definition of performance and everyone else’s is very different.
And I would urge shareholders to contact the company / Peter and voice your concerns as I will
They also mentioned a business update in March so to cement there pipeline as mentioned they will need to secure a hand full of new contracts very soon
If you have his email? i have always emailed JM
but on the other hand - pretty sure share holders shouldn't have to correct the BOD about things that they have actively said in the public domain and not followed through ?
Personally I do think this is clutching at straws... id love to be corrected.
What we need for starters is the BOD to actually provide and engage with the shareholders like they state numerous times in presentations but never seem to deliver.
This isnt a "deal" this is more of a collaboration/ study
Question…..Where does the Val scientific advisory board fit into all of this?
The Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
The time line from requisition to termination was 4th March - 30th April 2020 therefore for Suzy to leave could follow the same time line… therefore might not drag on forever.
They also mentioned there would be a business update in March and company investors presentation.
As you stated the company did state “watch this space” between now and there therefore logic would state there must be some solid news in the next 4 to 6 weeks
I agree with AIMGambler tbf….
Needs something to get it out of the 1’s something that is high 2’s or it will be in the 1-2 region for a while imo
Like it or not Porky is factually correct in what he says in terms of possibilities….process and timelines.
Val did it with there last CEO George Morris in favour of Suzy…..
In regards to PYC - Dr Sargent needs time and the reasons VAL or questioning the BOD as there has been historical promises never delivered and the share prices has been decimate.
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the appointment of Siegfried Braeuer to Director, International Sales. In this role, he will lead the expansion of DoseMe’s Model Informed Precision Dosing (MIPD) platform through channel partners and direct sales across multiple continents.
Siegfried Braeuer brings a wealth of experience in pharma with a long tenure at Merck. Additional roles at Swiss Alpinopharma, Amarin GmbH, Interim Management/Consulting and Canpharma, added to Siegfried ‘Sigi’ vast experience building teams across the emerging markets of the Eastern Europe, Middle East, and Africa region. Braeuer, an alumnus of Johannes Kepler University Linz and the MBA program at Emory University, joins DoseMe with more than 20 years of experience leading high-performance teams across pharmaceutical, commercialization and technology spanning multiple geographies including US, UK, Brazil and India.
“The healthcare industry is on a digital transformation journey and EMEA, MEA, Latin America and Asia are fast growing markets with the adoption of precision medicine on an upward trajectory,” said Paul Edwards, CEO of DoseMe. “I am confident that Sigi has the knowledge, skills, proven experience and passion to drive our vision forward and continue to make DoseMe the preferred choice for healthcare organizations.”
In the past year, the company has expanded its distribution network with exclusive resellers across 29 countries. DoseMe continues to focus on product innovation and go-to-market expansion to build new drug models to broaden the MTDM platform. Under Braeuer’s leadership, diversifying the channels and adding new partners will enable the company to offer a wide range of AI-powered systems for real-time patient care.
“DoseMe is at an inflection point as the advent of AI in precision dosing takes shape and is driving the increasing demand around the globe. I am excited to work with these exceptionally talented individuals to achieve our next phase of growth,” said Braeuer.
Peter Sargent new CEO isn’t getting a salary increase from COO
Jim Millen taking a considerable decrease
Who’s betting there is suddenly a contract RNS pretty soon…
And DR S is high fiving himself followed by a options RNS haaaaaa